https://ibmi.taiwan-healthcare.org/news_detail.php?REFDOCTYPID=&REFDOCID=0q5b3i6m8ej0s6w5；2)
Eva Tsai mark this message contains personal perspective
｜originally written by Eva Tsai
此訊息內容並非完全正確，包含有過度簡化、以及未經證實的訊息。
Opinion Sources
1. 瑞德西韋目前僅美國單一新型冠狀病毒個案有治療效果，仍需進行臨床試驗，因此稱為「救命藥」有誇大之嫌，請參：1) 生策會新聞：https://ibmi.taiwan-healthcare.org/news_detail.php?REFDOCTYPID=&REFDOCID=0q5b3i6m8ej0s6w5；2) Line訊息中連結內文(Yahoo新聞)所提及的新英格蘭醫學期刊病例報告：https://www.nejm.org/doi/full/10.1056/NEJMoa20011912. Line訊息中連結內文(Yahoo新聞)並未提及瑞德西韋的研發者，因此有標題與內文不符之嫌。經查證，開發瑞德西韋的公司Gilead Sciences，確實由台灣人Taiyin Yang擔任藥劑開發與製造執行副總裁，因此或可稱為該藥研發之推手，但無法查證是否由她本人進行研發：https://www.gilead.com/about/leadership/senior-management/taiyin-yang
First Case of 2019 Novel Coronavirus in the United States
Original ArticleBrief ReportList of authors.Michelle L. Holshue, M.P.H., Chas DeBolt, M.P.H., Scott Lindquist, M.D., Kathy H. Lofy, M.D., John Wiesman, Dr.P.H., Hollianne Bruce, M.P.H., Christopher Sp
Cannot get data from URL
The content above by Cofacts message reporting chatbot and crowd-sourced fact-checking community is licensed under Creative Commons Attribution-ShareAlike 4.0 (CC BY-SA 4.0), the community name and the provenance link for each item shall be fully cited for further reproduction or redistribution.